Rocket Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300R7VV82YUIN4Y93 - ISIN
US77313F1066 (RCKT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Read full profile
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€228.30M - EBIT margin
0.0% - Net income
-€219.46M - Net margin
0.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Bjork Elisabeth | N/A |
|
|
|
|
| Militello John | See Remarks |
|
|
|
|
| Schwartz Jonathan David | See Remarks |
|
|
|
|
| Wilson Martin | General Counsel |
|
|
|
|
| Militello John | See Remarks |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: August 9, 2021 (Q2 2021)